Pular para o conteúdo principal
Ranking Invest

RGEN - Repligen Corporation

Segmento: HealthcareRepligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Análise Ranking Invest

Valuation estimado
$ 2.26 Bi
Valor de Mercado
$ 9.32 Bi
Sobrepreço (AV)+312.2%
IVR
0.24A companhia vale 0,24 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
0.02O valuation alternativo equivale a 2% do valor de mercado da companhia.
MLL
0.02O lucro líquido dos controladores em 16 trimestres equivale a 2% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 2.11 Bi

Dívida Líquida

-$ 55.74 Mi

L4T

$ 41.54 Mi

MM4T

5.34%

Indicadores Básicos

ROE

1.97%

Índices de Previsibilidade

Receita Líquida

D0.09

Lucro

G9.13

Margem

F4.72

Índices de Tendência

Receita Líquida

C4.12

Lucro

F-5.07

Margem

F-4.94

Índices de Endividamento

DIV/PAT

-0.03

DIV/L4T

-1.34

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.